Losartan potassium mode of action
Pro Research Analysisby 
Searched over 200M research papers
Losartan Potassium Mode of Action
Introduction to Losartan Potassium
Losartan potassium is a groundbreaking antihypertensive medication belonging to the class of angiotensin II receptor antagonists (ARAs). It is primarily used to manage hypertension and reduce the risk of cardiovascular events such as strokes and myocardial infarctions Goa1996Goldberg1995. This article delves into the pharmacodynamics, pharmacokinetics, and clinical efficacy of losartan potassium, highlighting its unique mode of action.
Pharmacodynamics: Angiotensin II Receptor Antagonism
Selective AT1 Receptor Blockade
Losartan potassium functions by selectively and competitively binding to the angiotensin II subtype 1 (AT1) receptor, thereby inhibiting the physiological effects of angiotensin II (AII) Goa1996Burrell1997. This blockade prevents AII-induced vasoconstriction, sodium and fluid retention, increased sympathetic activity, and cellular growth, all of which are critical factors in cardiovascular homeostasis and hypertension Goa1996Burrell1997.
Active Metabolite E3174
An essential aspect of losartan's efficacy is its active metabolite, E3174, which binds to the AT1 receptor with ten times greater affinity than losartan itself. E3174 is significantly more potent in inhibiting AII-induced pressor and contractile responses, contributing substantially to the drug's antihypertensive effects Goa1996Burnier1995. This metabolite ensures a prolonged duration of action, maintaining blood pressure reduction throughout a 24-hour period after a single daily dose Goa1996Burnier1995.
Pharmacokinetics: Absorption, Metabolism, and Excretion
Bioavailability and Metabolism
Losartan potassium has a bioavailability of approximately 33%, indicating a significant first-pass effect. It is metabolized in the liver to form E3174, which is responsible for most of its pharmacological activity Goa1996Burrell1997. The time to peak plasma concentration is about one hour for losartan and three to four hours for E3174 .
Elimination and Half-Life
The terminal elimination half-life of E3174 is longer than that of losartan, ensuring sustained antihypertensive effects. The pharmacokinetics of losartan and E3174 are not significantly affected by renal dysfunction but are altered in patients with hepatic impairment, necessitating dosage adjustments Goa1996Burrell1997.
Clinical Efficacy and Safety
Blood Pressure Reduction
Losartan potassium effectively lowers blood pressure in patients with mild to moderate hypertension, with efficacy comparable to other antihypertensive agents such as enalapril, atenolol, and felodipine extended release Goa1996Mcintyre1997Goldberg1995. It is also effective in elderly patients and can be combined with hydrochlorothiazide for enhanced blood pressure reduction Goa1996Mcintyre1997.
Tolerability and Adverse Effects
Losartan potassium is well-tolerated, with dizziness being the only adverse effect reported more frequently than with placebo. It has a lower incidence of cough compared to ACE inhibitors, making it a suitable alternative for patients who experience ACE inhibitor-related cough Goa1996Burrell1997Bui1992. Additionally, losartan does not significantly affect renal function, lipid levels, or insulin sensitivity, and it has a favorable safety profile in long-term use Goa1996Burrell1997Bui1992.
Conclusion
Losartan potassium represents a significant advancement in the management of hypertension due to its selective AT1 receptor antagonism, effective blood pressure reduction, and favorable safety profile. Its active metabolite, E3174, plays a crucial role in its prolonged antihypertensive effects. With its unique mode of action and excellent tolerability, losartan potassium is well-positioned to be a prominent choice in the treatment of essential hypertension.
Sources and full results
Most relevant research papers on this topic
Modulating effect of losartan potassium on the mutagenicity and recombinogenicity of doxorubicin in somatic cells of Drosophila melanogaster.
Losartan potassium does not show a mutagenic effect on Drosophila melanogaster cells, but when combined with doxorubicin, it reduces the number of mutant spots without altering the recombinogenic effect of the chemotherapeutic agent.
DOI